{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T15:44:43Z","timestamp":1745941483791,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00280-022-04431-5","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T16:03:02Z","timestamp":1661529782000},"page":"697-705","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Is age just a number? A population pharmacokinetic study of gemcitabine"],"prefix":"10.1007","volume":"89","clinical-trial-number":[{"clinical-trial-number":"ntr-3964704812","registry":"10.18810\/dutch-trial-register"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6399-2604","authenticated-orcid":false,"given":"Ren\u00e9 J.","family":"Boosman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Rose B. S.","family":"Crombag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nielka P.","family":"van Erp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"4431_CR1","unstructured":"National Cancer Instistute. Age and cancer risk. http:\/\/www.cancer.gov. Accessed 20 Oct 2021"},{"issue":"10","key":"4431_CR2","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/bcp.14539","volume":"86","author":"RJ van Marum","year":"2020","unstructured":"van Marum RJ (2020) Underrepresentation of the elderly in clinical trials, time for action. Br J Clin Pharmacol 86(10):2014\u20132016. https:\/\/doi.org\/10.1111\/bcp.14539","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"4431_CR3","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/bcp.13876","volume":"85","author":"R Ruiter","year":"2019","unstructured":"Ruiter R, Burggraaf J, Rissmann R (2019) Under-representation of elderly in clinical trials: an analysis of the initial approval documents in the Food and Drug Administration database. Br J Clin Pharmacol 85(4):838\u2013844. https:\/\/doi.org\/10.1111\/bcp.13876","journal-title":"Br J Clin Pharmacol"},{"key":"4431_CR4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.maturitas.2016.06.021","volume":"93","author":"C Lucas","year":"2016","unstructured":"Lucas C, Byles J, Martin JH (2016) Medicines optimisation in older people: taking age and sex into account. Maturitas 93:114\u2013120. https:\/\/doi.org\/10.1016\/j.maturitas.2016.06.021","journal-title":"Maturitas"},{"key":"4431_CR5","unstructured":"European Medicines Agency. Gemzar: summary of product characteristics"},{"issue":"Suppl 5","key":"4431_CR6","doi-asserted-by":"publisher","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","volume":"17","author":"E Mini","year":"2006","unstructured":"Mini E, Nobili S, Caciagli B, Landini I, Mazzei T (2006) Cellular pharmacology of gemcitabine. Ann Oncol 17(Suppl 5):v7-12. https:\/\/doi.org\/10.1093\/annonc\/mdj941","journal-title":"Ann Oncol"},{"issue":"8","key":"4431_CR7","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1158\/1535-7163.Mct-08-0137","volume":"7","author":"SA Veltkamp","year":"2008","unstructured":"Veltkamp SA, Pluim D, van Eijndhoven MAJ, Bolijn MJ, Ong FHG, Govindarajan R et al (2008) New insights into the pharmacology and cytotoxicity of gemcitabine and 2\u2032,2\u2032-difluorodeoxyuridine. Mol Cancer Ther 7(8):2415\u20132425. https:\/\/doi.org\/10.1158\/1535-7163.Mct-08-0137","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"4431_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/03602530902722679","volume":"41","author":"U Klotz","year":"2009","unstructured":"Klotz U (2009) Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41(2):67\u201376. https:\/\/doi.org\/10.1080\/03602530902722679","journal-title":"Drug Metab Rev"},{"issue":"3","key":"4431_CR9","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ygyno.2013.05.001","volume":"130","author":"S Leijen","year":"2013","unstructured":"Leijen S, Veltkamp SA, Huitema AD, van Werkhoven E, Beijnen JH, Schellens JH (2013) Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer. Gynecol Oncol 130(3):511\u2013517. https:\/\/doi.org\/10.1016\/j.ygyno.2013.05.001","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4431_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.pan.2019.11.012","volume":"20","author":"X Li","year":"2020","unstructured":"Li X, Huang DB, Zhang Q, Guo CX, Fu QH, Zhang XC et al (2020) The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer. Pancreatology 20(1):95\u2013100. https:\/\/doi.org\/10.1016\/j.pan.2019.11.012","journal-title":"Pancreatology"},{"issue":"1","key":"4431_CR11","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jchromb.2006.03.023","volume":"835","author":"MN Kirstein","year":"2006","unstructured":"Kirstein MN, Hassan I, Guire DE, Weller DR, Dagit JW, Fisher JE et al (2006) High-performance liquid chromatographic method for the determination of gemcitabine and 2\u2032,2\u2032-difluorodeoxyuridine in plasma and tissue culture media. J Chromatogr B 835(1):136\u2013142. https:\/\/doi.org\/10.1016\/j.jchromb.2006.03.023","journal-title":"J Chromatogr B"},{"issue":"14","key":"4431_CR12","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1002\/rcm.3096","volume":"21","author":"LD Vainchtein","year":"2007","unstructured":"Vainchtein LD, Rosing H, Thijssen B, Schellens JH, Beijnen JH (2007) Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2\u2019,2\u2019-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry. Rapid Commun Mass Spectrom 21(14):2312\u20132322. https:\/\/doi.org\/10.1002\/rcm.3096","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"6","key":"4431_CR13","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s10637-015-0281-z","volume":"33","author":"R van der Noll","year":"2015","unstructured":"van der Noll R, Smit WM, Wymenga AN, Boss DS, Grob M, Huitema AD et al (2015) Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer. Invest New Drugs 33(6):1197\u20131205. https:\/\/doi.org\/10.1007\/s10637-015-0281-z","journal-title":"Invest New Drugs"},{"issue":"1","key":"4431_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00280-011-1670-4","volume":"69","author":"M Joerger","year":"2012","unstructured":"Joerger M, Burgers JA, Baas P, Doodeman VD, Smits PH, Jansen RS et al (2012) Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin\/gemcitabine. Cancer Chemother Pharmacol 69(1):25\u201333. https:\/\/doi.org\/10.1007\/s00280-011-1670-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"4431_CR15","volume-title":"Safety, pharmacokinetics and preliminary anti-tumor activity of novel (combinations of) targeted anti-cancer drugs","author":"R Van der Noll","year":"2014","unstructured":"Van der Noll R, Schellens JHM, Beijnen JH (2014) Safety, pharmacokinetics and preliminary anti-tumor activity of novel (combinations of) targeted anti-cancer drugs. Utrecht University, Utrecht"},{"issue":"6","key":"4431_CR16","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00280-010-1255-7","volume":"65","author":"O Caffo","year":"2010","unstructured":"Caffo O, Fallani S, Marangon E, Nobili S, Cassetta MI, Murgia V et al (2010) Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 65(6):1197\u20131202. https:\/\/doi.org\/10.1007\/s00280-010-1255-7","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"4431_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2165\/11532970-000000000-00000","volume":"49","author":"E Sugiyama","year":"2010","unstructured":"Sugiyama E, Kaniwa N, Kim S-R, Hasegawa R, Saito Y, Ueno H et al (2010) Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients. Clin Pharmacokinet 49(8):549\u2013558. https:\/\/doi.org\/10.2165\/11532970-000000000-00000","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"4431_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1365-2125.2007.03040.x","volume":"65","author":"X Jiang","year":"2008","unstructured":"Jiang X, Galettis P, Links M, Mitchell PL, McLachlan AJ (2008) Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. Br J Clin Pharmacol 65(3):326\u2013333. https:\/\/doi.org\/10.1111\/j.1365-2125.2007.03040.x","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"4431_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31\u201341. https:\/\/doi.org\/10.1159\/000180580","journal-title":"Nephron"},{"issue":"6","key":"4431_CR20","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s10928-016-9487-8","volume":"43","author":"AG Dosne","year":"2016","unstructured":"Dosne AG, Bergstrand M, Harling K, Karlsson MO (2016) Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling. J Pharmacokinet Pharmacodyn 43(6):583\u2013596. https:\/\/doi.org\/10.1007\/s10928-016-9487-8","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"4431_CR21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s12603-018-1129-y","volume":"23","author":"M Serra-Prat","year":"2019","unstructured":"Serra-Prat M, Lorenzo I, Palomera E, Ram\u00edrez S, Y\u00e9benes JC (2019) Total body water and intracellular water relationships with muscle strength, frailty and functional performance in an elderly population. A cross-sectional study. J Nutr Health Aging 23(1):96\u2013101. https:\/\/doi.org\/10.1007\/s12603-018-1129-y","journal-title":"J Nutr Health Aging"},{"issue":"2","key":"4431_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1152\/ajplegacy.1950.162.2.313","volume":"162","author":"JM Steele","year":"1950","unstructured":"Steele JM, Berger EY, Dunning MF, Brodie BB (1950) Total body water in man. Am J Physiol Legacy Content 162(2):313\u2013317. https:\/\/doi.org\/10.1152\/ajplegacy.1950.162.2.313","journal-title":"Am J Physiol Legacy Content"},{"issue":"26","key":"4431_CR23","doi-asserted-by":"publisher","first-page":"8482","DOI":"10.3748\/wjg.v20.i26.8482","volume":"20","author":"S Nordh","year":"2014","unstructured":"Nordh S, Ansari D, Andersson R (2014) hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review. World J Gastroenterol 20(26):8482\u20138490. https:\/\/doi.org\/10.3748\/wjg.v20.i26.8482","journal-title":"World J Gastroenterol"},{"issue":"4","key":"4431_CR24","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/annonc\/mdm576","volume":"19","author":"D Santini","year":"2008","unstructured":"Santini D, Perrone G, Vincenzi B, Lai R, Cass C, Alloni R et al (2008) Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer. Ann Oncol 19(4):724\u2013728. https:\/\/doi.org\/10.1093\/annonc\/mdm576","journal-title":"Ann Oncol"},{"issue":"7","key":"4431_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2174\/138920011796504527","volume":"12","author":"S Shi","year":"2011","unstructured":"Shi S, Klotz U (2011) Age-related changes in pharmacokinetics. Curr Drug Metab 12(7):601\u2013610. https:\/\/doi.org\/10.2174\/138920011796504527","journal-title":"Curr Drug Metab"},{"key":"4431_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.726669","author":"P Rattanacheeworn","year":"2021","unstructured":"Rattanacheeworn P, Kerr SJ, Kittanamongkolchai W, Townamchai N, Udomkarnjananun S, Praditpornsilpa K et al (2021) Quantification of CYP3A and drug transporters activity in healthy young, healthy elderly and chronic kidney disease elderly patients by a microdose cocktail approach. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2021.726669","journal-title":"Front Pharmacol"},{"issue":"11","key":"4431_CR27","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1124\/dmd.111.040790","volume":"39","author":"LS Hodge","year":"2011","unstructured":"Hodge LS, Taub ME, Tracy TS (2011) The deaminated metabolite of gemcitabine, 2\u2032,2\u2032-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase. Drug Metab Dispos 39(11):2013\u20132016. https:\/\/doi.org\/10.1124\/dmd.111.040790","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 55","key":"4431_CR28","first-page":"2773","volume":"38","author":"N Secen","year":"2011","unstructured":"Secen N, Sazdanic-Velikic D, Bursac D, Mendebaba B, Tepavac A, Popovic G et al (2011) Hematological toxicity associated with gemcitabine\/cisplatin in elderly non-small cell lung cancer patients. Eur Respirat J 38(Suppl 55):2773","journal-title":"Eur Respirat J"},{"issue":"3","key":"4431_CR29","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00280-019-03895-2","volume":"84","author":"U Ishimoto","year":"2019","unstructured":"Ishimoto U, Kinoshita A, Hirose Y, Shibata K, Ishii A, Shoji R et al (2019) The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients. Cancer Chemother Pharmacol 84(3):647\u2013654. https:\/\/doi.org\/10.1007\/s00280-019-03895-2","journal-title":"Cancer Chemother Pharmacol"},{"key":"4431_CR30","doi-asserted-by":"publisher","first-page":"v259","DOI":"10.1093\/annonc\/mdx369.139","volume":"28","author":"J Ventriglia","year":"2017","unstructured":"Ventriglia J, Laterza MM, Savastano B, Petrillo A, Tirino G, Pompella L et al (2017) Safety and efficacy of gemcitabine\/nabpaclitaxel in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: a retrospective analysis. Ann Oncol 28:v259. https:\/\/doi.org\/10.1093\/annonc\/mdx369.139","journal-title":"Ann Oncol"},{"issue":"10","key":"4431_CR31","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s40266-014-0207-z","volume":"31","author":"MBS Crombag","year":"2014","unstructured":"Crombag MBS, de Vries Schultink AHM, Schellens JHM, Beijnen JH, Huitema ADR (2014) Incidence of hematologic toxicity in older adults treated with gemcitabine or a gemcitabine-containing regimen in routine clinical practice: a multicenter retrospective cohort study. Drugs Aging 31(10):737\u2013747. https:\/\/doi.org\/10.1007\/s40266-014-0207-z","journal-title":"Drugs Aging"},{"issue":"6","key":"4431_CR32","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/00130404-200511000-00005","volume":"11","author":"M Sehl","year":"2005","unstructured":"Sehl M, Sawhney R, Naeim A (2005) Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J 11(6):461\u2013473. https:\/\/doi.org\/10.1097\/00130404-200511000-00005","journal-title":"Cancer J"},{"issue":"9","key":"4431_CR33","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1007\/s12603-020-1404-6","volume":"24","author":"FM Runzer-Colmenares","year":"2020","unstructured":"Runzer-Colmenares FM, Urrunaga-Pastor D, Roca-Moscoso MA, De Noriega J, Rosas-Carrasco O, Parodi JF (2020) Frailty and vulnerability as predictors of chemotherapy toxicity in older adults: a longitudinal study in Peru. J Nutr Health Aging 24(9):966\u2013972. https:\/\/doi.org\/10.1007\/s12603-020-1404-6","journal-title":"J Nutr Health Aging"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04431-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-022-04431-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04431-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T16:08:51Z","timestamp":1661530131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-022-04431-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["4431"],"URL":"https:\/\/doi.org\/10.1007\/s00280-022-04431-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2022,4,15]]},"assertion":[{"value":"27 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.J. Boosman, M.B.S. Crombag and A.D.R. Huitema declare that they have no conflict of interest. N.P. van Erp received research grant from Astellas, Janssen-Cilag and Ipsen. J.H. Beijnen has received payment for expert testimony for Hoyng Tokh Monegier (paid to their institution), is a part-time employee and (in)direct stockholder of Modra Pharmaceuticals and (jointly) holds a patent on oral taxane formulations, which are clinically developed by Modra Pharmaceuticals. Modra Pharmaceuticals is a small spin-off company of the Netherlands Cancer Institute. All of these conflicts are outside of the submitted work. N. Steeghs provided consultation or attended advisory boards for Boehringer Ingelheim, Ellipses Pharma. N Steeghs received research grants for the institute from AB Science, Abbvie, Actuate Therapeutics, ADCtherapeutics, Amgen, Array, Ascendis Pharma, Astex, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol-Myers Squibb, Cantargia, Celgene, CellCentric, Cresecendo, Cytovation, Deciphera, Eli Lilly, Exelixis, Genentech, Genmab, Gilead, GlaxoSmithKline, Incyte, InteRNA, Janssen\/Johnson&Johnson, Kinate, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Novartis, Numab, Pfizer, Pierre Fabre, Regeneron, Roche, Sanofi, Seattle Genetics, Servier, Taiho, Takeda (outside the submitted work).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}